Enjamb Labs GTM brain

Enjamb sells AI agents to biopharma teams that carry out research, clinical, regulatory and quality work across existing systems.

category

AI agents for biopharma operations

market profile

  • text: Drug programs span scientific, clinical and regulatory systems, making handoffs and institutional knowledge difficult to maintain.
  • text: The company reports use by teams at more than 130 biopharma companies across 34 countries; this is a vendor claim.

personas

  • title: Head of clinical operations
    pains:
    • Study, site and CRO work is scattered across systems
    • Handoffs lose the context needed to move studies forward
  • title: Biometrics or statistical programming lead
    pains:
    • Turning database lock into a review-ready package requires coordinated work
    • Traceability and review consume expert time
  • title: Regulatory and quality leader
    pains:
    • Submission responses require locating approved source material
    • Automated actions must be attributable and auditable
  • title: Biopharma IT or digital transformation leader
    pains:
    • Legacy scientific systems and custom internal tools do not share a common agent layer
    • Security and permissions complicate deployment

icp

  • text: Biotech and pharmaceutical companies with discovery through clinical, regulatory or quality programs.
  • text: Teams using systems such as Benchling, Veeva or Medidata alongside internal LIMS and collaboration tools.
  • text: Organizations with multi-team drug programs that require controlled, reviewable workflows.

message pillars

  • text: Agents operate inside existing scientific systems.
  • text: Agents operate through familiar collaboration channels.
  • text: Actions follow named user permissions and retain an audit record.
  • text: Shared institutional knowledge survives handoffs.

objections

  • objection: Can an agent work within our security and validation requirements?
    response: Review the named-user permissions and audit records, then validate each intended workflow with quality and security teams.
  • objection: Do we need to migrate scientific systems?
    response: Enjamb describes connectors to existing systems and internal tools; confirm coverage for each deployment.
  • objection: Will it replace scientific judgment?
    response: Enjamb positions agents as executing work while domain experts retain judgment; pilot a reviewable task.

competitors

  • name: Alchemi
    why: Develops tailored AI agents for pharma development and regulatory submissions.
  • name: Veeva
    why: Life sciences platform with workflow tools across clinical and regulatory use cases; also an Enjamb integration.
  • name: Elicit
    website: https://elicit.com/ai-for-pharma
    why: AI research and evidence workflows overlap with Enjamb's scientific research use cases.

influencers

  • name: Rayan Mubarak
    url: https://www.ycombinator.com/founders/rayan-mubarak
    why: Enjamb founder and public spokesperson.

keywords

  • biopharma AI agents
  • clinical operations automation
  • AI regulatory submissions
  • biometrics workflow automation
  • pharma AI scientific research
  • Veeva AI integration
  • life sciences agent audit trail

voice

  • domain-specific
  • assured
  • scientific and operational

signals

  • text: A drug developer is expanding clinical studies and struggling with CRO or site handoffs.
  • text: A biopharma company uses multiple disconnected scientific systems and is evaluating AI deployment.
  • text: A regulatory team is preparing submissions with approved documents spread across systems.

stack

  • Benchling
  • Veeva
  • Medidata Rave
  • CDD Vault
  • Seqera
  • Latch
  • Slack
  • Microsoft Teams
  • Google Chat
  • MCP

hiring

  • Founding Applied AI Engineer
  • Founding Product Engineer
  • Founding Infra Engineer
  • Founding Sales Lead
  • Chief of Staff
  • Scientific Solutions Lead
  • Customer Success Manager

pricing

model: unknown

motion

sales_led

channels

  • product website
  • YC launch
  • demo requests

confidence

high

Founders

  • name: Rayan Mubarak
    title: Founder/CEO
    role: CEO
    bio: Co-founder of Enjamb. I'm an ML and biology researcher. At 17, I published a first-author cancer ML paper in JMIR that beat SOTA models by 20%. Previously, I researched drug therapeutics for pesticide poisoning (30% more effective) and presented at top bio conferences (SOT, ISCB).

Back to YC companies